This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Histologically confirmed advanced breast cancer
* Age ≥18 years
* Expected survival \>3 months
* Willing to undergo ctDNA testing and sign informed consent form
Exclusion Criteria:
* The subject has not signed the informed consent form.
* Pregnant or breastfeeding women.
* Other situations deemed by the investigator as unsuitable for inclusion in the study.
Primary outcome measure(s)
Overall Survival (OS) — From diagnosis until death or study completion, up to 3 years
Trial sites (1)
Facility
City
Region
Status
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.